For patients with metastatic castration-resistant prostate cancer (mCRPC) unselected for homologous recombination r ...

For patients with metastatic castration-resistant prostate cancer (mCRPC) unselected for homologous recombination repair (HRR ...

Treatment (Rx) patterns and attrition rates in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC). Real world comparison of time-to-next-treatment (TTNT), ...

The FDA has granted fast track status to 67Cu-SAR-bisPSMA for metastatic prostate cancer that is resistant to hormone therapy ...

with metastatic castration-resistant prostate cancer (mCRPC). Study of JAK inhibition in stem-like prostate cancer (JASPER): A phase 1/2 multicenter study of ruxolitinib and enzalutamide in castration ...

Talzenna is a poly (ADP-ribose) polymerase (PARP) inhibitor indicated for: HRR gene-mutated mCRPC: In combination with enzalutamide for the treatment of adult patients with homologous recombination ...

such as enzalutamide and abiraterone, have validated the androgen receptor and secondary androgen production as crucial targets in metastatic castration-resistant prostate cancer (mCRPC).

An expert discusses the therapeutic options included in the NCCN guidelines for metastatic castration-resistant prostate ...

Intravenous; mCRPC: Metastatic castration-resistant prostate ... Abiraterone acetate plus prednisone and enzalutamide improve overall survival (OS) and radiological progression-free survival ...